How does NTRK fusion affect Melanoma treatment options

MelanomaMay 17, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

NTRK Fusion and Melanoma Treatment

I appreciate your question about NTRK fusion in melanoma. Let me provide you with what the current evidence shows.

What the Guidelines Say

Based on the NCCN Guidelines for Patients: Melanoma (2025), which I have access to, NTRK fusion testing is not currently listed as a standard biomarker that oncologists routinely test for or use to guide melanoma treatment decisions.

The NCCN guidelines focus on these key biomarkers for melanoma:

BRAF mutations (V600 mutations specifically) - which DO guide treatment with targeted therapies like dabrafenib/trametinib
PD-L1 expression - which helps determine immunotherapy approaches
CDKN2A mutations - relevant for genetic risk assessment

Why This Matters

NTRK fusions are well-established treatment targets in other cancer types (like certain lung cancers, thyroid cancers, and pediatric cancers), where they respond to drugs called TRK inhibitors. However, NTRK fusions appear to be extremely rare in cutaneous melanoma (the most common type of skin melanoma), which is why they're not part of standard testing protocols.

What You Should Do

If you or your care team believe NTRK testing might be relevant to your specific situation:

Questions to ask your oncologist:

"Is NTRK fusion testing recommended for my type of melanoma?"
"What biomarkers are you testing for in my case, and why?"
"Are there any clinical trials involving TRK inhibitors that might be appropriate for me?"
"Should I pursue genetic testing beyond the standard BRAF and other markers?"

Important Context

Your oncologist will determine which biomarker tests are appropriate based on:

Your specific melanoma type (cutaneous vs. mucosal vs. uveal)
Your stage of disease
Your treatment history
The latest research findings

According to the NCCN Guidelines, the standard approach focuses on BRAF testing and immunotherapy markers, which have strong evidence supporting their use in melanoma care.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Upload Records →Ask About Your Case →

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →